Explore evidence

36 %In Kisumu, seroprevalence of anti-SARS-CoV-2 IgG was 36.0% (95% CI 28.2–44.4%) at the beginning of the study period.

KenyaCOVID-19published 2022PLOS global public healtheurope_pmcdocument of 7 observationsDOI 10.1371/journal.pgph.0000883

288 patientsThe study included 288 patients with critical COVID-19 admitted to the Aga Khan University Hospital, Nairobi between 1st March 2020 and 31st December 2021.

KenyaCOVID-19observed 1st March 2020 to 31st December 2021published 2024PloS onePubMeddocument of 18 observations

By May 2021 in three broadly representative populations of unvaccinated individuals in Kenya, seroprevalence of anti-SARS-CoV-2 IgG was 25–50%.

KenyaCOVID-19observed May 2021published 2022PLOS global public healtheurope_pmcdocument of 7 observationsDOI 10.1371/journal.pgph.0000883

50 %The Alpha variant was detected in 50.0% of persons aged 31 to 45 years among SARS-CoV-2 cases in Laikipia county, Kenya.

KenyaCOVID-19observed 24th April to 31st December 2021published 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument of 10 observations

6 genomesAll six recovered SARS-CoV-2 genomes classified within the 501Y.V2 variant of concern (lineage B.1.351).

Kenya501Y.V2 variant of concern · COVID-19 · lineage B.1.351published 2021Wellcome open researcheurope_pmcdocument of 3 observations

3.78 odds_ratioOmicron was associated with cough (odds ratio 3.78; 95% CI 1.1–16.74, p = 0.026) relative to other SARS-CoV-2 variants of concern in Laikipia county, Kenya.

KenyaCOVID-19observed 24th April to 31st December 2021published 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument of 10 observations

24.9 %Among 1,123 hospitalized COVID-19 patients in Kenya, 24.9% had severe disease.

KenyaCOVID-19published 2025Global health actionPubMeddocument of 11 observations

38.9 %Among patients with underlying conditions in Kenya's hospitalized COVID-19 cohort, diabetes was present in 38.9%.

KenyaCOVID-19 · diabète (non précisé)published 2025Global health actionPubMeddocument of 11 observations

92.7 %The Platelia Total Ab Assay and the Mount Sinai spike IgG ELISA showed a high qualitative agreement of 92.7% in detecting SARS-CoV-2 antibodies in a mother-infant cohort in Nairobi, Kenya.

KenyaCOVID-19observed May 2019 to December 2020published 2023Journal of medical virologyPubMeddocument of 3 observations

78 introduction_eventsAt least 78 independent SARS-CoV-2 introduction events occurred in Seychelles between 14 March 2020 and 31 December 2021.

KenyaCOVID-19observed 2020-03-14 to 2021-12-31published 2022Viruseseurope_pmcdocument of 3 observationsDOI 10.3390/v14061318

33 %Few participants had symptoms: 33% of infants experienced symptoms of SARS-CoV-2 infection.

KenyaCOVID-19observed between May 1, 2020-February 1, 2022published 2023PloS onePubMeddocument of 8 observations

0.58 odds_ratioThe odds of survival from COVID-19 disease were lower among cases aged ≥60 years (odds ratio = 0.58, P = 0.034).

KenyaCOVID-19published 2022Journal of global healthPubMeddocument of 24 observations

0.58 odds_ratioThe odds of survival from COVID-19 disease were lower among cases with underlying conditions (odds ratio = 0.58, P = 0.025).

KenyaCOVID-19published 2022Journal of global healthPubMeddocument of 24 observations

3.35 odds_ratioThe odds of survival from COVID-19 disease were higher among transport sector employees (odds ratio = 3.35, P = 0.004).

KenyaCOVID-19published 2022Journal of global healthPubMeddocument of 24 observations

9,941 patientsBetween July 2022 and October 2023, a total of 9941 patients with severe respiratory illness were enrolled, of whom 588 (5.9%) tested positive for SARS-CoV-2.

Kenya · MaliCOVID-19observed July 2022 to October 2023published 2026VaccinePubMeddocument of 8 observations

0.973 RThe Platelia Total Ab Assay and the Mount Sinai spike IgG ELISA showed a strong correlation of antibody levels with R = 0.973 in repeated measures in a mother-infant cohort in Nairobi, Kenya.

KenyaCOVID-19observed May 2019 to December 2020published 2023Journal of medical virologyPubMeddocument of 3 observations

44 %SARS-CoV-2 seropositivity was found in 44% of the 125 infants in Nairobi, Kenya.

KenyaCOVID-19observed between May 1, 2020-February 1, 2022published 2023PloS onePubMeddocument of 8 observations

51.4 %The Omicron variant was detected in 51.4% of persons aged 16 to 30 years among SARS-CoV-2 cases in Laikipia county, Kenya.

KenyaCOVID-19observed 24th April to 31st December 2021published 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument of 10 observations

41.5 %If SARS-CoV-2 self-testing were available, 41.5% of participants would be very likely to use it.

KenyaCOVID-19observed August 2021published 2022International journal of public healtheurope_pmcdocument of 6 observations

43 yearsThe median age of hospitalized SARS-CoV-2-infected patients was 43 years (IQR 30–53), and 505 (64%) were men.

KenyaCOVID-19published 2022BMJ openPubMeddocument of 7 observations

Within a mother-infant cohort in Nairobi, Kenya, seroprevalence detected by either the Platelia Total Ab Assay or the Mount Sinai spike IgG ELISA closely resembled previously published seroprevalence estimates for Kenya during the sampling period from May 2019 to December 2020.

KenyaCOVID-19observed May 2019 to December 2020published 2023Journal of medical virologyPubMeddocument of 3 observations

31.8 %Among 1893 cases with likely sources of exposure in Kenya, 601 (31.8%) were due to international travel.

KenyaCOVID-19published 2022Journal of global healthPubMeddocument of 24 observations

Kenya detected the first case of COVID-19 on March 13, 2020.

KenyaCOVID-19observed March 13, 2020published 2022Journal of global healthPubMeddocument of 24 observations

2.82 aORMortality during COVID-19 hospitalization was nearly threefold higher among patients with heart disease (adjusted odds ratio [aOR] 2.82).

KenyaCOVID-19 · heart diseasepublished 2025Global health actionPubMeddocument of 11 observations

10 days52 (7%) of hospitalized SARS-CoV-2-infected patients were ventilated for a mean of 10 days.

KenyaCOVID-19published 2022BMJ openPubMeddocument of 7 observations